Ronald M. Bukowski

45.0k citations
459 papers · 34.0k indexed · 7 hit papers · h-index 77
Topics
Renal cell carcinoma treatment (201 papers)Renal and related cancers (94 papers)Cancer Genomics and Diagnostics (92 papers)

In The Last Decade

Ronald M. Bukowski

457 papers receiving 33.2k citations

Hit Papers

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell...20062026201220192007200720092009200610002.0k3.0k4.0k

Peers

Ronald M. Bukowski
Comparison fields: 5 of 154
  • Pulmonary and Respiratory Medicine 19.9k
  • Molecular Biology 17.7k
  • Oncology 13.4k
  • Cancer Research 10.3k
  • Immunology 4.6k
Replace Robert A. Figlin with:
Robert A. Figlin United States
Brian I. Rini United States
Bernard Escudier France
Stéphane Oudard France
Martin Gore United Kingdom
Robert J. Motzer United States
Cezary Szczylik Poland
Walter M. Stadler United States
Camillo Porta Italy
Jean‐Charles Soria France
Ronald M. Bukowski relative to Robert A. Figlin United States Robert A. Figlin's profile →
Citations per field
00.5×1.5×
Robert A. Figlin · 1×
Citations per year

Countries citing papers authored by Ronald M. Bukowski

Since Specialization
Citations

This map shows the geographic impact of Ronald M. Bukowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald M. Bukowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald M. Bukowski more than expected).

Fields of papers citing papers by Ronald M. Bukowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald M. Bukowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald M. Bukowski. The network helps show where Ronald M. Bukowski may publish in the future.

Co-authorship network of co-authors of Ronald M. Bukowski

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald M. Bukowski. A scholar is included among the top collaborators of Ronald M. Bukowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald M. Bukowski. Ronald M. Bukowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 3
2 148
3
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinomabreakdown →
1711
4
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trialbreakdown →
864
5 378
6
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patientsbreakdown →
690
7 3
8 30
9 321
10
Comparative efficacy of sunitinib administered on an intermittent or a continuous daily dosing schedule in metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) patients predicted using population PK approaches
4
11 311
12
A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC).
7
13 10
14
Preliminary pharmacokinetic evaluation of Albuleukin; an interleukin-2 human serum albumin fusion protein, in solid tumor patients
9
15 22
16 100
17 16
18
Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
17
19
Renal cell carcinoma : immunotherapy and cellular biology
13
20
Combination chemotherapy including VP-16 in poor prognosis germinal cell neoplasms
1

About Ronald M. Bukowski

Ronald M. Bukowski is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 459 papers that have together received 34.0k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (201 papers), Renal and related cancers (94 papers) and Cancer Genomics and Diagnostics (92 papers). The work is most often cited by research in Cancer Research (10.3k citations), Pulmonary and Respiratory Medicine (19.9k citations) and Oncology (13.4k citations). Ronald M. Bukowski has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Thomas E. Hutson, Robert J. Motzer, Cezary Szczylik, Sylvie Négrier, Stéphane Oudard, M. Dror Michaelson, Robert A. Figlin, Brian I. Rini, Sindy T. Kim and Bernard Escudier. Their work appears in journals such as New England Journal of Medicine, The Lancet and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026